Business Context and Reporting Period
Karyopharm Therapeutics Inc. (KPTI) filed a Form 8-K on January 12, 2026, reporting preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company, incorporated in Delaware, focuses on XPOVIO (selinexor) and related license agreements.
Key Financial Metrics
| Metric | Q4 2025 (Est.) | Full Year 2025 (Est.) |
|---|---|---|
| Total Revenue | $33 million | $145 million |
| U.S. XPOVIO Net Product Revenue | $32 million | $115 million |
| Cash, Cash Equivalents, Restricted Cash, and Investments | $64 million (as of Dec 31, 2025) |
Note: The filing does not provide specific figures for net profit, operating margins, debt levels, or cash flow from operations.
Material Changes and Comparisons
The filing text does not provide comparative data for the prior year or quarter to determine material changes in revenue or profitability. The reported figures represent management's preliminary estimates for the 2025 period.
Outlook, Liquidity, and Risks
- Liquidity: Management expects existing liquidity, combined with anticipated revenue from XPOVIO sales and license agreements, to fund planned operations into the second quarter of 2026.
- Unusual Items/Contingencies: All financial figures presented are preliminary and unaudited. They are subject to completion of financial closing procedures and have not been audited or reviewed by the company's independent registered public accounting firm.
- Legal Disclaimer: The information in Item 2.02 and the accompanying press release is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act.
Investor Verification Checklist
- Verify the final audited revenue figures once the annual report (10-K) is filed, as current numbers are preliminary estimates.
- Confirm the exact cash runway and whether the company will require additional capital before the second quarter of 2026.
- Review the breakdown of the $30 million difference between total revenue and U.S. XPOVIO net product revenue to understand the contribution of license and royalty income.
- Monitor for any updates on the company's debt obligations, which are not detailed in this filing.